| 1 |
33962209 | The study of Raddeanin A cerebrovascular endothelial cell trafficking through P-glycoprotein. | 2021 Jun 25 |
1 |
| 2 |
29146563 | Characterization of the IPEC-J2 MDR1 (iP-gp) cell line as a tool for identification of P-gp substrates. | 2018 Jan 15 |
1 |
| 3 |
29673999 | Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. | 2018 Aug |
3 |
| 4 |
30108983 | Live-cell fluorescence imaging: assessment of thioflavin T uptake in human epidermal carcinoma cells. | 2018 Jun 1 |
1 |
| 5 |
24524365 | The cell line NCl-H441 is a useful in vitro model for transport studies of human distal lung epithelial barrier. | 2014 Mar 3 |
1 |
| 6 |
22228402 | Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin. | 2012 Jul |
1 |
| 7 |
21148080 | Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). | 2011 Mar |
1 |
| 8 |
17583464 | Role of xenobiotic efflux transporters in resistance to vincristine. | 2008 Feb |
1 |
| 9 |
18157518 | Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). | 2008 Feb |
2 |
| 10 |
17454628 | Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma. | 2007 Apr |
1 |
| 11 |
15809877 | Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours. | 2005 Aug |
1 |
| 12 |
14718607 | Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir. | 2004 Mar |
2 |
| 13 |
15161679 | A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy. | 2004 May 15 |
3 |
| 14 |
15257929 | Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. | 2004 Jul |
1 |
| 15 |
12455064 | Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. | 2003 Jan 1 |
10 |
| 16 |
12712010 | Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. | 2003 Mar-Apr |
1 |
| 17 |
11331075 | Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells. | 2001 Jun 1 |
4 |
| 18 |
11356921 | Effect of capillary efflux transport inhibition on the determination of probe recovery during in vivo microdialysis in the brain. | 2001 Jun |
1 |
| 19 |
10783828 | Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP). | 2000 Apr |
1 |
| 20 |
10820137 | Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. | 2000 Jun |
1 |
| 21 |
10869171 | Effects of cholesterol and enantiomeric cholesterol on P-glycoprotein localization and function in low-density membrane domains. | 2000 Jul 4 |
2 |
| 22 |
10374882 | Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents. | 1999 May |
1 |
| 23 |
10411602 | Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. | 1999 Aug |
8 |